Nabriva Therapeutics plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nabriva Therapeutics plc.
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.
With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Other Names / Subsidiaries
- Zavante Therapeutics, Inc.